| Literature DB >> 18578879 |
Susan I Jarvi1, Margaret E M Farias, Carter T Atkinson.
Abstract
BACKGROUND: The relatively recent introduction of a highly efficient mosquito vector and an avian pathogen (Plasmodium relictum) to an isolated island ecosystem with naïve, highly susceptible avian hosts provides a unique opportunity to investigate evolution of virulence in a natural system. Mixed infections can significantly contribute to the uncertainty in host-pathogen dynamics with direct impacts on virulence. Toward further understanding of how host-parasite and parasite-parasite relationships may impact virulence, this study characterizes within-host diversity of malaria parasite populations based on genetic analysis of the trap (thrombospondin-related anonymous protein) gene in isolates originating from Hawaii, Maui and Kauai Islands.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18578879 PMCID: PMC2464593 DOI: 10.1186/1745-6150-3-25
Source DB: PubMed Journal: Biol Direct ISSN: 1745-6150 Impact factor: 4.540
Details regarding the samples include bird identification and species, isolate of P. relictum and island of origin of isolate; details regarding the methods include enzyme/buffer system and number of cycles for amplification, and method of amplification and cloning*
| 1 (764) | K1 | Survivor Day 89 PI | Kauai | Promega | 80 | PCR+1 | 20 | 4 | 16 | 0 | |
| 2 (1145) | K1 | Survivor Day 81 PI | Kauai | Promega | 80 | PCR+1 | 20 | 6 | 16 | 1 | |
| 3 (1187) | K1 | Survivor Day 69 PI | Kauai | Promega | 80 | PCR+1 | 20 | 5 | 17 | 0 | |
| 4 (584) | K1 | Fatality Day 16 PI | Kauai | Promega | 80 | standard | 17 | 4 | 15 | 1 | |
| Promega | 80 | PCR+1 | 20 | 5 | 18 | 1 | |||||
| 5 (591) | K1 | Fatality Day 19 PI | Kauai | Promega | 80 | standard | 9 | 4 | 9 | 0 | |
| Promega | 80 | PCR+1 | 20 | 5 | 17 | 1 | |||||
| 6 (593) | K1 | Fatality Day 19 PI | Kauai | Promega | 80 | standard | 10 | 2 | 5 | 0 | |
| Promega | 80 | PCR+1 | 20 | 5 | 16 | 0 | |||||
| Promega | 35 | PCR+1 | 19 | 3 | 15 | 0 | |||||
| Roche | 35 | PCR+1 | 20 | 2 | 20 | 10 | |||||
| 7 (601) | KV115 | Fatality Day 16 PI | Hawaii | Promega | 80 | PCR+1 | 20 | 5 | 16 | 1 | |
| 8 (613) | KV115 | Fatality Day 23 PI | Hawaii | Promega | 80 | standard | 9 | 5 | 8 | 0 | |
| 9 (736) | KV115 | Survivor Day 81 PI | Hawaii | Promega | 80 | PCR+1 | 20 | 8 | 17 | 4 | |
| 10 (620) | KV115 | Fatality Day 24 PI | Hawaii | Promega | 80 | standard | 17 | 7 | 17 | 0 | |
| Promega | 80 | PCR+1 | 20 | 5 | 17 | 1 | |||||
| 11 (623) | KV115 | Fatality Day 26 PI | Hawaii | Promega | 80 | standard | 9 | 2 | 6 | 0 | |
| Promega | 80 | PCR+1 | 20 | 4 | 13 | 0 | |||||
| Promega | 35 | PCR+1 | 20 | 4 | 18 | 0 | |||||
| Roche | 35 | PCR+1 | 20 | 2 | 18 | 10 | |||||
| 12 (1757) | wild | Blood 4/20/96 | Kauai | Promega | 80 | standard | 8 | 3 | 6 | 1 | |
| 13 (1765) | wild | Blood 4/5/95 | Hawaii | Promega | 80 | standard | 9 | 5 | 9 | 1 | |
| 14 (1818) | wild | Blood 3/28/95 | Hawaii | Promega | 80 | standard | 10 | 5 | 9 | 0 | |
| 15 (1928) | wild | Blood 11/16/93 | Maui | Promega | 80 | standard | 3 | 1 | 2 | 0 | |
| 16 (2881) | wild | Blood 2/3/95 | Kauai | Promega | 80 | standard | 9 | 4 | 8 | 1 | |
| 17 (3186) | wild | Blood 3/13/96 | Kauai | Promega | 80 | standard | 7 | 6 | 6 | 1 | |
| 18 (6775) | wild | Blood 4/24/01 | Hawaii | Promega | 80 | standard | 1 | 1 | 1 | 1 | |
| Totals | 397 | 335 | 33 | ||||||||
*Details regarding the clones include total number produced, number of confirmed (detected in > 1 bird) variants and clones, as well as the number of clones sequenced. Blood was collected from experimentally-infected birds that survived infection between days 69–89 post-infection (PI) when parasitemias had reached chronic levels. Pectoral muscle was collected from experimentally-infected birds that succumbed to infection between days 16–26 PI when acute phase parasitemias were high.
Summary* of haplotype detection, diversity estimates and information regarding hosts infected with K1, KV115 or wild isolates.
| Isolate K1 | Isolate KV115 | Wild Isolates | ||||||||||||||||
| Bird ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| Species | H | H | H | H | H | H | H | H | H | H | H | H | I | A | H | E | E | H |
| Island | K | K | K | K | K | K | H | H | H | H | H | K | H | H | M | K | K | H |
| Survivorship | S | S | S | F | F | F | F | F | S | F | F | ND | ND | ND | ND | ND | ND | ND |
| 1289 bp site | P | P | ND | P | P | P | A | ND | A | A | A | A | P | ND | ND | A | P | A |
| Haplotype 1 | 1 | 1 | ||||||||||||||||
| 3 | 1 | 1 | ||||||||||||||||
| 4 | 2 | 1 | ||||||||||||||||
| 8 | 1 | 1 | 1 | 1 | 1 | |||||||||||||
| 10 | 1 | 1 | ||||||||||||||||
| 12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||
| 20 | 2 | 1 | 1 | 1 | 2 | |||||||||||||
| 25 | 1 | 1 | 1 | |||||||||||||||
| 27 | 1 | 3 | ||||||||||||||||
| 30 | 1 | 1 | 2 | 1 | ||||||||||||||
| 33 | 1 | 1 | 1 | 1 | 1 | |||||||||||||
| 34 | 1 | 1 | 1 | |||||||||||||||
| 36 | 1 | 1 | ||||||||||||||||
| 41 | 2 | 1 | 1 | |||||||||||||||
| 44 | 1 | 1 | ||||||||||||||||
| 45 | 1 | 1 | 1 | |||||||||||||||
| 47 | 1 | 2 | 1 | |||||||||||||||
| 49 | 1 | 2 | ||||||||||||||||
| 51 | 1 | 1 | ||||||||||||||||
| 53 | 1 | 1 | ||||||||||||||||
| 56 | 1 | 1 | ||||||||||||||||
| 57 | 1 | 1 | 1 | 1 | ||||||||||||||
| 58 | 1 | 1 | ||||||||||||||||
| 59 | 1 | 2 | 1 | 1 | ||||||||||||||
| 61 | 1 | 1 | 1 | |||||||||||||||
| 62 | 1 | 3 | ||||||||||||||||
| 73 | 1 | 1 | ||||||||||||||||
| 77 | 13 | 11 | 11 | 26 | 19 | 47 | 12 | 4 | 10 | 24 | 44 | 4 | 4 | 5 | 2 | 5 | 1 | 0 |
| Total Haplotypes | 3 | 6 | 5 | 8 | 7 | 8 | 5 | 5 | 8 | 10 | 8 | 3 | 4 | 5 | 1 | 4 | 6 | 1 |
| Total # clones | 16 | 16 | 17 | 33 | 26 | 56 | 16 | 8 | 17 | 34 | 55 | 6 | 9 | 9 | 2 | 8 | 6 | 1 |
| Freq. Hap 77 | 0.81 | 0.69 | 0.65 | 0.79 | 0.73 | 0.57 | 0.75 | 0.5 | 0.59 | 0.71 | 0.8 | 0.67 | 0.44 | 0.56 | n/a | 0.63 | 0.17 | n/a |
| D (Simpson's) | 1.49 | 2.03 | 2.21 | 1.59 | 1.83 | 1.41 | 1.73 | 3.2 | 2.7 | 1.97 | 1.55 | 2 | 3.24 | 2.79 | n/a | 2.29 | 6 | n/a |
| H (S-W) | 0.69 | 1.12 | 1.12 | 0.93 | 1.05 | 0.91 | 0.91 | 1.39 | 1.48 | 1.24 | 0.87 | 0.87 | 1.27 | 1.3 | n/a | 1.07 | 1.79 | n/a |
| Hap/Clones ratio | 0.19 | 0.38 | 0.29 | 0.24 | 0.27 | 0.15 | 0.31 | 0.63 | 0.47 | 0.29 | 0.15 | 0.50 | 0.44 | 0.56 | n/a | 0.50 | 1.00 | n/a |
*Birds are identified as in Table 1. Species are abbreviated as: H (Hawaiian 'Amakihi), I (I'iwi), A ('Apapane), and E (Elepaio). Island abbreviations are: K (Kauai), H (Hawai'i), M (Maui). Survivorship to malaria challenge is abbreviated as: F (fatality) and S (survivor). Designations at the 1289 bp site are either the amino acid P (proline) or A (alanine). ND (no data).
Figure 1A rarefaction curve provides comparable estimates of species richness (ES). The number of estimated haplotypes are plotted against the number of clones. The 95% confidence intervals are as indicated by dotted lines above (higher) and below (lower).
Summary of RFLP-defined haplotype diversity estimates* by isolate and survivorship.
| Isolates | Survivorship | ||||
| KV115 | K1 | Wild | Survivors | Non-survivors | |
| Number of birds | 5 | 6 | 5 | 4 | 7 |
| Haplotypes | 20 | 24 | 14 | 16 | 18 |
| Total # clones | 130 | 164 | 38 | 66 | 97 |
| Freq. Hap 77 | 0.72 | 0.77 | 0.55 | 0.68 | 0.92 |
| D(Simpson's) | 1.89 | 1.66 | 3.03 | 2.11 | 1.85 |
| H(S-W) | 1.37 | 1.2 | 1.97 | 1.45 | 1.32 |
| Hap/Clones ratio | 0.15 | 0.15 | 0.37 | 0.24 | 0.18 |
* Kruskal-Wallis Rank Test for K1 and KV115: for D, Mann-Whitney U test statistic = 9.000, P = 0.273, for H, Mann-Whitney U test statistic = 8.000, P = 0.201, for Hap/clones ratio, Mann-Whitney U test statistic = 8.000, P = 0.199. Kruskal-Wallis Rank Test for Surivors and Non-survivors: for D, Mann-Whitney U test statistic = 19.000, P = 0.345, for H, Mann-Whitney U test statistic = 16.000, P = 0.705, for Hap/clone ratio, Mann-Whitney U test statistic = 18.500, P = 0.393.
Diversity estimate summation of side-by-side comparisons of enzyme/buffer system, cycling parameters and PCR methodology in two 'Amakihi infected with isolate K1 and KV115.
| Bird ID Isolate | 'Amakihi 6 K1 Kauai | 'Amakihi 11 KV115 Hawaii | ||||||
| Enzyme | Promega | Roche | Promega | Roche | ||||
| Methods | Standard | PCR+1 | Standard | PCR+1 | ||||
| # cycles | 80 | 80 | 35 | 35 | 80 | 80 | 35 | 35 |
| Trial 1 | Trial 2 | Trial 3 | Trial 4 | Trial 1 | Trial 2 | Trial 3 | Trial 4 | |
| Haplotype 4 | 1 | |||||||
| 12 | 1 | |||||||
| 25 | 1 | 1 | ||||||
| 27 | 2 | 1 | ||||||
| 33 | 1 | |||||||
| 45 | 1 | |||||||
| 47 | 1 | |||||||
| 49 | 1 | 1 | ||||||
| 56 | 1 | |||||||
| 58 | 1 | |||||||
| 59 | 2 | |||||||
| 62 | 1 | 3 | ||||||
| 77 | 4 | 11 | 13 | 19 | 5 | 8 | 15 | 16 |
| Haplotypes | 2 | 5 | 3 | 2 | 2 | 4 | 4 | 2 |
| Total # Clones | 5 | 16 | 15 | 20 | 6 | 13 | 18 | 18 |
| Freq. Hap 77 | 0.8 | 0.69 | 0.87 | 0.95 | 0.83 | 0.62 | 0.83 | 0.89 |
| D (Simpson's) | 1.47 | 2 | 1.32 | 1.1 | 1.38 | 2.25 | 1.42 | 1.24 |
| H (S-W) | 0.5 | 1.04 | 0.49 | 0.2 | 0.45 | 1.03 | 0.63 | 0.35 |
| Hap/Clone Ratio | 0.40 | 0.31 | 0.20 | 0.10 | 0.33 | 0.31 | 0.22 | 0.11 |
Figure 2Schematic of a TRAP gene showing relevant domains.
Figure 3Haplotype network of the partial TRAP gene generated in TCS (vers 1.21). The maximum number of steps connecting parsimoniously two haplotypes is indicated by circular nodes. The haplotype with the highest outgroup probability is boxed, all others displayed as ovals. All haplotypes are represented by single sequences unless otherwise indicated by multiple sequence designations. The numerical sequence designations are as follows: bird number. clone number/RFLP haplotype designation.